Cancer News and Research

Latest Cancer News and Research

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

DNAnexus announces new cloud-based tools for analyzing large-scale genomic variation datasets

DNAnexus, Inc., a leading provider of cloud-based solutions for analyzing, visualizing, and managing next-generation sequencing data, today announced the availability of a comprehensive set of new informatics tools that enable life science researchers to efficiently analyze and manage large-scale genomic variation datasets in a cloud-based workflow.

3 Feb 2011

Researchers design nanoparticles that make blood clots visible to CT scanner

For almost two decades, cardiologists have searched for ways to see dangerous blood clots before they cause heart attacks. Now, researchers at Washington University School of Medicine in St. Louis report that they have designed nanoparticles that find clots and make them visible to a new kind of X-ray technology.

3 Feb 2011

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

A team of scientists from the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9 million grant from the California Institute for Regenerative Medicine to fund development of a new technique to aid pharmaceutical discoveries for specific diseases.

3 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.

3 Feb 2011

Agilent introduces first commercial RNA target enrichment system

Agilent Technologies, Inc., today introduced SureSelect RNA Capture Kits, the first commercial RNA target enrichment system enabling geneticists to focus on specific genomic loci or transcripts of research interest. The RNA capture kits make it possible to precisely measure expression levels of genes of interest and detect allelic-specific expression, splicing events and gene fusions.

3 Feb 2011

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.

3 Feb 2011

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Seattle Genetics, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price to the public of $15.50 per share.

3 Feb 2011

Scientists challenged to sequence genome and RNA content derived from single cancer cell

Life Technologies Corporation today announced that the Life Grand Challenges Contest, initially introduced in December 2010, is expanding to include a fourth challenge. This latest contest challenges scientists to sequence the genome and all RNA content derived from a single cancer cell using the 5500 Series SOLiD™ Sequencers.

3 Feb 2011

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer.

2 Feb 2011

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.

2 Feb 2011

USPTO issues notice of allowance to Vermillion's breast cancer biomarkers

Vermillion, a molecular diagnostics company, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent entitled "Biomarkers for breast cancer" to the Company.

2 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

Scil Proteins concludes financing round with BioNet Holding for €24 million

Scil Proteins today announced that it has concluded a financing round with its existing investor, BioNet Holding, worth €24 million. The funds are intended to finance the development of two products derived from the Company's Affilin platform into clinical Phase I over the next three years.

2 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

Cell Press launches new iPhone application for downloading research articles

Cell Press is delighted to announce the launch of its new iPhone app - Cell Alerts, available to download for free at www.cell.com/iphone or http://bit.ly/fw9pbx.

2 Feb 2011

Elsevier acquires Cancer Information Group's oncology journals portfolio

Elsevier, the leading global publisher of scientific, technical, and medical information products and services, announced today that it acquired the oncology portfolio of journals previously published by CIG Media Group LP., (operated as Cancer Information Group).

2 Feb 2011

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

An innovative diabetes management concept including structured self-monitoring of blood glucose (SMBG), data visualization, pattern analysis and derived therapy adjustments can significantly reduce HbA1c values, improve glycemic control and enhance patients' quality of life. These are the key findings of the 12-month data from the Structured Testing Protocol (STeP) Study, newly published in Diabetes Care.

2 Feb 2011

New study finds mate guarding common in societies which practice arranged marriages

Mate guarding is classified as excessive or unwarranted jealous or protective behavior towards a spouse or mate. This is common among many different species and can be useful to defend territory, guarantee paternity, or prevent disease. The authors of a new study published in Personal Relationships have discovered that this behavior is more common in societies which practice arranged marriages or in cultures that place a high value on parental influence in the choice of mate for their children.

2 Feb 2011

Cancer News and Research

Latest Cancer News and Research

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

DNAnexus announces new cloud-based tools for analyzing large-scale genomic variation datasets

Researchers design nanoparticles that make blood clots visible to CT scanner

Cedars-Sinai receives California Institute grant to develop new technique for specific diseases

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Largazole appears to be an ideal blueprint for developing new drugs against bone diseases

Agilent introduces first commercial RNA target enrichment system

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Scientists challenged to sequence genome and RNA content derived from single cancer cell

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

Isis commences ISIS-FXIRx Phase 1 study for treatment of clotting disorders

USPTO issues notice of allowance to Vermillion's breast cancer biomarkers

Researchers discover potential vaccine capable of reducing H. pylori colonization

Scil Proteins concludes financing round with BioNet Holding for €24 million

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

Cell Press launches new iPhone application for downloading research articles

Elsevier acquires Cancer Information Group's oncology journals portfolio

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

New study finds mate guarding common in societies which practice arranged marriages

Industry Focus eBook - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in